SecSonar.com

Vericel Corporation (VCEL)

Vericel Corporation at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Vericel Corporation (VCEL) is a Biotechnology company based in US with a market capitalization of $1.7B. Revenue grew 16.4% year-over-year and the company generated $24.7M in free cash flow. This page tracks VCEL's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 357 employees · IPO Feb 4, 1997

Valuation

Valuation & price

$33.03 · as of May 17, 2026 · -28.7% vs 52w high

104.1

P/E ratio

Latest-FY diluted EPS

4.85

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$46.35$37.84$29.34Jul 25Dec 25Jul 26Jul 7, 25$39.41Jul 9, 25$41.50Jul 11, 25$39.93Jul 15, 25$37.10Jul 17, 25$36.26Jul 21, 25$35.46Jul 23, 25$40.35Jul 25, 25$40.12Jul 29, 25$39.86Jul 31, 25$34.94Aug 4, 25$37.58Aug 6, 25$36.29Aug 11, 25$35.43Aug 13, 25$37.93Aug 15, 25$36.28Aug 19, 25$36.17Aug 21, 25$35.44Aug 25, 25$35.79Aug 27, 25$35.89Aug 29, 25$36.36Sep 3, 25$33.55Sep 5, 25$34.05Sep 9, 25$32.54Sep 11, 25$33.53Sep 16, 25$33.23Sep 18, 25$31.85Sep 22, 25$31.81Sep 24, 25$30.25Sep 26, 25$30.23Sep 30, 25$31.47Oct 2, 25$31.52Oct 6, 25$33.74Oct 8, 25$34.13Oct 10, 25$31.85Oct 14, 25$34.64Oct 16, 25$34.75Oct 21, 25$36.45Oct 23, 25$35.99Oct 27, 25$36.47Oct 29, 25$34.88Oct 31, 25$35.06Nov 4, 25$36.25Nov 6, 25$38.75Nov 10, 25$38.99Nov 12, 25$40.44Nov 14, 25$39.86Nov 18, 25$39.03Nov 20, 25$37.85Nov 25, 25$42.54Nov 28, 25$40.25Dec 2, 25$37.65Dec 4, 25$36.79Dec 8, 25$37.30Dec 10, 25$37.64Dec 12, 25$36.54Dec 16, 25$35.50Dec 18, 25$36.16Dec 22, 25$37.37Dec 24, 25$37.56Dec 29, 25$37.59Jan 2, 26$35.61Jan 6, 26$39.34Jan 8, 26$40.73Jan 12, 26$36.59Jan 14, 26$37.33Jan 16, 26$37.40Jan 21, 26$37.72Jan 23, 26$37.85Jan 27, 26$36.58Jan 29, 26$36.50Feb 2, 26$36.94Feb 4, 26$36.88Feb 9, 26$35.44Feb 11, 26$34.63Feb 13, 26$35.96Feb 18, 26$37.41Feb 20, 26$38.09Feb 24, 26$38.25Feb 26, 26$37.68Mar 2, 26$35.36Mar 4, 26$34.96Mar 6, 26$33.71Mar 10, 26$33.40Mar 12, 26$32.11Mar 17, 26$32.50Mar 19, 26$32.74Mar 23, 26$32.45Mar 25, 26$31.44Mar 27, 26$29.34Mar 31, 26$32.17Apr 2, 26$34.14Apr 7, 26$33.33Apr 9, 26$33.59Apr 13, 26$34.44Apr 15, 26$35.37Apr 17, 26$35.68Apr 22, 26$34.37Apr 24, 26$35.64Apr 28, 26$35.65Apr 30, 26$34.73May 4, 26$36.49May 6, 26$36.78May 8, 26$33.46May 12, 26$32.94May 14, 26$33.14May 18, 26$34.87May 20, 26$35.40May 22, 26$34.73May 28, 26$34.24Jun 1, 26$32.82Jun 3, 26$34.74Jun 5, 26$36.30Jun 9, 26$37.03Jun 11, 26$38.57Jun 15, 26$38.29Jun 17, 26$39.13Jun 22, 26$40.47Jun 24, 26$41.69Jun 26, 26$46.23Jul 2, 26$46.35
$29.3452-week range$46.35
Loading valuation history…

Fundamentals

Key fundamentals

$1.7B

Market cap

16.4%

Revenue growth (YoY)

74.4%

Gross margin

$24.7M

Free cash flow (USD)

-$39.2M

Net debt

Net cash position

3.6%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$54.4MFY 2017$63.9MFY 2018$90.9MFY 2019$117.8MFY 2020$124.2MFY 2021$156.2MFY 2022$164.4MFY 2023$197.5MFY 2024$237.2MFY 2025$276.3M
$54.4M$276.3M

Free cash flow by year

2016 → 2025

FY 2016$-21.3MFY 2017$-14.7MFY 2018$-3.1MFY 2019$-9.8MFY 2020$14.9MFY 2021$21.1MFY 2022$10.1MFY 2023$7.8MFY 2024$-5.8MFY 2025$24.7M
-$21.3M$24.7M

Gross margin by year

2021 → 2025

FY 202167.9%FY 202266.8%FY 202368.6%FY 202472.5%FY 202574.4%
67.9%74.4%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

4

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 7, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • Insider sellInsider Sell $224K · 10b5-1 PlanMara Joseph Anthony Jr · Chief Financial Officer · $223.8KJun 30, 2026Filing
  • Insider sellInsider Sell $123K · 10b5-1 PlanSIEGAL JONATHAN · Principal Accounting Officer · $122.7KJun 30, 2026Filing
  • Insider sellInsider Sell $603K · 10b5-1 PlanFlynn Sean C. · Chief Legal Officer · $603.2KJun 22, 2026Filing
  • Insider sellInsider Sell $402K · 10b5-1 PlanHalpin Michael · Chief Operating Officer · $402.4KJun 22, 2026Filing
  • 8-K eventBylaws AmendedMay 18, 2026Filing
  • 8-K eventEarnings ReleaseMay 7, 2026Filing
  • Quarterly report10-Q FiledMay 7, 2026Filing
  • 8-K eventAnnual Meeting ResultsMay 1, 2026Filing

Questions

Frequently asked questions

What is Vericel Corporation's market cap?

Vericel Corporation (VCEL) has a market capitalization of $1.7B.

What is VCEL's P/E ratio?

VCEL trades at a price-to-earnings ratio of 104.1, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

What is VCEL's price-to-book (P/B) ratio?

VCEL trades at 4.85 times book value per share.

Are insiders buying VCEL stock?

SEC Form 4 filings show no open-market insider buys at Vericel Corporation in the last 90 days (4 sells).

Same arena

Related companies in Biotechnology

SNDX

Syndax Pharmaceuticals, Inc.

$1.7B

ATAI

Atai Beckley N.V

$1.7B

AGIO

Agios Pharmaceuticals, Inc.

$1.8B

OCS

Oculis Holding AG

$1.7B

NUVB

Nuvation Bio Inc.

$1.6B

NVAX

Novavax, Inc.

$1.8B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.